Maeda Tadao, Mandai Michiko, Sugita Sunao, Kime Cody, Takahashi Masayo
Research Center, Kobe City Eye Hospital, Kobe 6500-047, Japan; Kobe City Eye Hospital, Department of Ophthalmology, Kobe 6500-047, Japan; Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan.
Research Center, Kobe City Eye Hospital, Kobe 6500-047, Japan; Kobe City Eye Hospital, Department of Ophthalmology, Kobe 6500-047, Japan; Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan; Vision Care Inc., Kobe 650-0047, Japan.
Trends Mol Med. 2022 May;28(5):388-404. doi: 10.1016/j.molmed.2022.03.001. Epub 2022 Apr 1.
Stem cell-based therapy for retinal degeneration is transitioning from the research stage to the clinical stage and is being developed as a treatment across the globe. In clinical studies on induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) transplantation, the safety of the technique has started to clarify, and clinical study on further advances such as the long-desired transplantation of iPSC-derived retina to treat retinitis pigmentosa (RP) has begun. Ophthalmologists are now working closely with basic researchers to incorporate new technology areas with a synergy that is anticipated to realize the practical application of stem cell-based therapy for retinal degeneration.
基于干细胞的视网膜变性治疗正从研究阶段过渡到临床阶段，并在全球范围内作为一种治疗方法进行开发。在关于诱导多能干细胞（iPSC）衍生的视网膜色素上皮（RPE）移植的临床研究中，该技术的安全性已开始明确，并且关于进一步进展的临床研究已经开始，例如长期以来期望的iPSC衍生视网膜移植治疗色素性视网膜炎（RP）。眼科医生现在正与基础研究人员密切合作，以一种有望实现基于干细胞的视网膜变性治疗实际应用的协同作用整合新的技术领域。
